Pharmacy and Medically Underserved Areas Enhancement Act

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 2617/H.R. 1244; Reducing Drug Prices for Seniors Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act H.R. 4317; PBM Reform Act H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services S.4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,282,990 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8324; Great American Healthcare Plan H.R. 9228; Health Data Access, Transparency, and Affordability Act of 2026 H.R. 9486; Health Data Access, Transparency and Affordability Act H.R. 9117; Clear Healthcare Expense Cost Knowledge Act H.R. 9393; Lower Cost, More Transparency Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,282,990 · Firm income: Not reported

S.891, the Bipartisan Health Care Act; S.882, the Patients Before Middlemen Act; S.927, the Protecting Pharmacies in Medicaid Act; H.R.3164/S.2426, the Mainstreet Pharmacy Access Act/the Ensuring Community Access to Pharmacist Services Act; H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act; Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169); Long-Term Care Pharmacy at Home Services in Medicare; Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)' H.R.1, the One Big Beautiful Bill Act Comments to CMS on "Re: Draft Guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program"; Comments to CMS on "Re: Medicare Transaction Facilitator DRAFT Standard Companion Guide Health Care Claim Payment/Advice (835)" Comments to CMS on "Re: Agency Information Collection Activities: Proposed Collection; Comment Request [Docket No. CMS-10912] - CMS-10912 Medicare Transaction Facilitator for 2026 and 2027 under Sections 11001 and 11002 of the Inflation Reduction Act (IRA) - Drug Price Negotiation Program MTF DM Dispensing Entity and Third-Party Support Enrollment Form"; H.Con.Res.14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R.4317, the PBM Reform Act; H.R.5031/S.3159, the Preserving Patient Access to Long-Term Care Pharmacies Act; Comments to CMS on "RE:Re: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model [CMS-1830-P]"; Comments to CMS on "Re: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies [CMS-1828-P]"; Comments to CMS on "RE:Re: 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program [HRSA2025 and HRSA-2025-14619]"; Comments to CMS on "Re: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program [CMS-1832-P]"; H.R.5256, the 340B ACCESS Act; S.2800, the Pharmacy and Medically Underserved Areas Enhancement Act; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; Grassley-Lujan Request-for-Information on Pharmacists Providing Chronic Care; CMMI Potential reimbursement model for CMS coverage of GLP-1 drugs; H.R.7148, the Consolidated Appropriations Act, 2026; Comments to CMS on Proposed Rule "Re: Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program"; Implementation of "reasonable and relevant" contract terms in the Medicare Part D Program; Comments to CMS on "Re: Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges [CMS-0062-P]"; Comments to CMS on "Re: Medicare GLP-1 Bridge Program - Improper Restriction of the $5.00 LTC Dispensing Fee to Nursing Facility and ICF/IID Residents; Conflict with 42 C.F.R. 423.120, Chapter 5, Section 20.7 of the Medicare Prescription Drug Benefit Manual, and CMSs December 15, 2021 Guidance on LTC Pharmacy Access";

S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3822; Break Up Big Medicine Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $2,996,995 · Firm income: Not reported

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 2617/H.R. 1244; Reducing Drug Prices for Seniors Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act H.R. 4317; PBM Reform Act H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $2,996,995 · Firm income: Not reported

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

S.891, the Bipartisan Health Care Act; S.882, the Patients Before Middlemen Act; S.927, the Protecting Pharmacies in Medicaid Act; H.R.3164/S.2426, the Ensuring Community Access to Pharmacist Services Act; H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act; Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169); Long-Term Care Pharmacy at Home Services in Medicare; Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)' H.R.1, the One Big Beautiful Bill Act Comments to CMS on "Re: Draft Guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program"; Comments to CMS on "Re: Medicare Transaction Facilitator DRAFT Standard Companion Guide Health Care Claim Payment/Advice (835)" Comments to CMS on "Re: Agency Information Collection Activities: Proposed Collection; Comment Request [Docket No. CMS-10912] - CMS-10912 Medicare Transaction Facilitator for 2026 and 2027 under Sections 11001 and 11002 of the Inflation Reduction Act (IRA) - Drug Price Negotiation Program MTF DM Dispensing Entity and Third-Party Support Enrollment Form"; H.Con.Res.14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R.4317, the PBM Reform Act; H.R.5031/S.3159, the Preserving Patient Access to Long-Term Care Pharmacies Act; Comments to CMS on "RE:Re: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model [CMS-1830-P]"; Comments to CMS on "Re: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies [CMS-1828-P]"; Comments to CMS on "RE:Re: 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program [HRSA2025 and HRSA-2025-14619]"; Comments to CMS on "Re: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program [CMS-1832-P]"; H.R.5256, the 340B ACCESS Act; S.2800, the Pharmacy and Medically Underserved Areas Enhancement Act; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; Grassley-Lujan Request-for-Information on Pharmacists Providing Chronic Care; CMMI Potential reimbursement model for CMS coverage of GLP-1 drugs; H.R.7148, the Consolidated Appropriations Act, 2026; Comments to CMS on Proposed Rule "Re: Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program"; Implementation of "reasonable and relevant" contract terms in the Medicare Part D Program;

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 2617/H.R. 1244; Reducing Drug Prices for Seniors Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act H.R. 4317; PBM Reform Act H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $299,699 · Firm income: Not reported

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3822; Break Up Big Medicine Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $299,699 · Firm income: Not reported

S.891, the Bipartisan Health Care Act; S.882, the Patients Before Middlemen Act; S.927, the Protecting Pharmacies in Medicaid Act; H.R.3164/S.2426, the Ensuring Community Access to Pharmacist Services Act; H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act; Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169); Long-Term Care Pharmacy at Home Services in Medicare; Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)' H.R.1, the One Big Beautiful Bill Act Comments to CMS on "Re: Draft Guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program"; Comments to CMS on "Re: Medicare Transaction Facilitator DRAFT Standard Companion Guide Health Care Claim Payment/Advice (835)" Comments to CMS on "Re: Agency Information Collection Activities: Proposed Collection; Comment Request [Docket No. CMS-10912] - CMS-10912 Medicare Transaction Facilitator for 2026 and 2027 under Sections 11001 and 11002 of the Inflation Reduction Act (IRA) - Drug Price Negotiation Program MTF DM Dispensing Entity and Third-Party Support Enrollment Form"; H.Con.Res.14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R.4317, the PBM Reform Act; H.R.5031/S.3159, the Preserving Patient Access to Long-Term Care Pharmacies Act; Comments to CMS on "RE:Re: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model [CMS-1830-P]"; Comments to CMS on "Re: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies [CMS-1828-P]"; Comments to CMS on "RE:Re: 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program [HRSA2025 and HRSA-2025-14619]"; Comments to CMS on "Re: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program [CMS-1832-P]"; H.R.5256, the 340B ACCESS Act; S.2800, the Pharmacy and Medically Underserved Areas Enhancement Act; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; Grassley-Lujan Request-for-Information on Pharmacists Providing Chronic Care; CMMI Potential reimbursement model for CMS coverage of GLP-1 drugs;

H.R. 1 One Big Beautiful Bill Act H.R. 2484 Seniors Access to Critical Medications Act H.R. 2853 Combating Organized Retail Crime Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 526 Pharmacy Benefit Manager (PBM) Transparency Act S. 527 Prescription Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 1404 Combating Organized Retail Crime Act S. 2426 Equitable Community Access to Pharmacist Services Act S. 2800 Pharmacy and Medically Underserved Areas Enhancement Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act H.R. 6575 CommonGround for Affordable Health Care Act H.R. 6501 Bipartisan Health Insurance Affordability Act H.R. 5256 340B ACCESS Act

Client expense: $360,000 · Firm income: Not reported

H.R. 2484 Seniors Access to Critical Medications Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 2626 Equitable Community Access to Pharmacist Services Act S. 2800 Pharmacy and Medically Underserved Areas Enhancement Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act H.R. 6575 CommonGround for Affordable Health Care Act H.R. 6501 Bipartisan Health Insurance Affordability Act

Client expense: $360,000 · Firm income: Not reported

H.R. 1, the One Big, Beautiful Bill Act Improving seniors' timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs S. 998, Medical Supply Chain Resiliency Act PAMA reform S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine LCD legislation HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts HR 5392, the Timely Access to Coverage Decisions Act of 2023 Remote digital telepathology HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 3248 - Diagnostic Lab Testing Transparency Act HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act Gene Therapy PREVAIL HR 6371 - budget neutrality bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S. 1546/H.R. 3152 The Patent Eligibility Restoration Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 S. 4935, Physician Fee Stabilization Act Medical Lab Personnel Shortage Relief Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act CDC Division of Cancer Prevention and Control and cancer registries appropriations S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 HR 3164 - Ensuring Community Access to Pharmacy Services Act (ECAPS) S 2800 - Pharmacy and Medically Underserved Areas Enhancement Act S 2420 / H.R. 4710 - No Surprises Act Enforcement Act S 2793 - Ensuring Access to Essential Providers Act of 2025 H.R. 5582 / S 2355 - Patients Deserve Price Tags Act Issues related to tariffs Issues related to public health

S.891, the Bipartisan Health Care Act; S.882, the Patients Before Middlemen Act; S.927, the Protecting Pharmacies in Medicaid Act; H.R.3164/S.2426, the Ensuring Community Access to Pharmacist Services Act; H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act; Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169); Long-Term Care Pharmacy at Home Services in Medicare; Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)' H.R.1, the One Big Beautiful Bill Act Comments to CMS on "Re: Draft Guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program"; Comments to CMS on "Re: Medicare Transaction Facilitator DRAFT Standard Companion Guide Health Care Claim Payment/Advice (835)" Comments to CMS on "Re: Agency Information Collection Activities: Proposed Collection; Comment Request [Docket No. CMS-10912] - CMS-10912 Medicare Transaction Facilitator for 2026 and 2027 under Sections 11001 and 11002 of the Inflation Reduction Act (IRA) - Drug Price Negotiation Program MTF DM Dispensing Entity and Third-Party Support Enrollment Form"; H.Con.Res.14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R.4317, the PBM Reform Act; H.R.5031, the Preserving Patient Access to Long-Term Care Pharmacies Act; Comments to CMS on "RE:Re: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model [CMS-1830-P]"; Comments to CMS on "Re: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies [CMS-1828-P]"; Comments to CMS on "RE:Re: 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program [HRSA2025 and HRSA-2025-14619]"; Comments to CMS on "Re: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program [CMS-1832-P]"; H.R.5256, the 340B ACCESS Act; S.2800, the Pharmacy and Medically Underserved Areas Enhancement Act;

H.R. 1 One Big Beautiful Bill Act H.R. 2484 Seniors Access to Critical Medications Act H.R. 2853 Combating Organized Retail Crime Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 526 Pharmacy Benefit Manager (PBM) Transparency Act S. 527 Prescription Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 1404 Combating Organized Retail Crime Act S. 2426 Equitable Community Access to Pharmacist Services Act S. 2800 Pharmacy and Medically Underserved Areas Enhancement Act

Client expense: $340,000 · Firm income: Not reported

H.R. 2484 Seniors Access to Critical Medications Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 2626 Equitable Community Access to Pharmacist Services Act S. 2800 Pharmacy and Medically Underserved Areas Enhancement Act

Client expense: $340,000 · Firm income: Not reported

H.R. 1, the One Big, Beautiful Bill Act H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Improving seniors' timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs S. 998, Medical Supply Chain Resiliency Act S 106 / HR 539 - Chiropractic Medicare Coverage Modernization Act PAMA reform HR 2483, Support for Patients and Communities Reauth Act HR 2484, Seniors access to Critical medications act Reducing Hereditary Cancer Act S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S 1830 - the Right to Treat Act S 1811 - Prohibits Graduate medical schools from receiving Federal assistance if DEI policies are in place S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine S 2066, Medicare transaction Fraud prevention act LCD legislation S 1866 - National Breast and Cervical Cancer Early Detection Program S 1882 - to expand research and training on reproductive health conditions HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act CDC Division of Cancer Prevention and Control and cancer registries appropriations S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 HR 3164 - Ensuring Community Access to Pharmacy Services Act (ECAPS) S 2800 - Pharmacy and Medically Underserved Areas Enhancement Act S 2420 / H.R. 4710 - No Surprises Act Enforcement Act S 2793 - Ensuring Access to Essential Providers Act of 2025 H.R. 5582 / S 2355 - Patients Deserve Price Tags Act Issues related to tariffs Issues related to public health